Stage 4 pancreatic cancer treatment centers on combination chemotherapy (FOLFIRINOX, gemcitabine/nab-paclitaxel), single-agent regimens, targeted therapies for actionable mutations, and thorough palliative care, selected primarily by performance status (ECOG 0-1 vs. 2 vs. 3-4) and treatment goals (life extension vs. Quality of life). Key Takeaways FOLFIRINOX and gemcitabine/nab-paclitaxel serve as first-line chemotherapy options, selected by ECOG performance status, age, and

TL;DR Stage 4 pancreatic cancer treatment focuses on controlling disease progression, managing symptoms, and maintaining quality of life rather than cure, with median survival of 11 months for FOLFIRINOX and 8.5 months for gemcitabine-based regimens [1] Dr. Bharat Patodiya provides personalized stage 4 treatment protocols combining chemotherapy, targeted therapy, and comprehensive supportive care through multidisciplinary coordination Only 49.1% of stage 4 pancreatic cancer p